Isolated in 2004 by Laurens and co-workers from root extracts of the West African plant, *Uvaria chamae*, chamuvarinin (**1**, Scheme [1](#sch1){ref-type="scheme"})^[@ref1],[@ref2]^ is a unique member of the annonaceous acetogenin family of natural products.([@ref3]) The crude extracts of *Uvaria chamae* are widely used in traditional medicinal practices for the treatment of a range of ailments including parasitic-borne West African sleeping sickness and has proven to be a rich source of novel acetogenins.([@ref4]) An initial biological screening of chamuvarinin showed significant cytotoxicity toward KB 3-1 cervix cancer cell lines (IC~50~ = 0.8 nM). Structurally, chamuvarinin is the first acetogenin to contain a tetrahydropyran (THP) ring linked adjacently to a bis-tetrahydrofuran (THF) ring system, spanning the C15−28 region of the carbon backbone. In common with the majority of acetogenins,([@ref3])**1** bears the 36S-configuration, but the assignment of the relative and absolute configuration within the C15−C28 region proved to be a more significant challenge. This quandary was partially resolved by Poupon and co-workers in 2007,([@ref2]) who showed that **1** is not derived directly from squamocin leading to the proposed relative configuration as shown,^[@ref3],[@ref5]^ with two possible diastereomeric structures for the structure of **1**. Herein, we report the total synthesis of chamuvarinin and stereochemical assignment of **1**, utilizing a highly convergent strategy for the construction of the central C15−C28 region. We chose to pursue the 15*R*-diastereomeric series based on a comparison of acetogenins bearing a C15-carbinol linked to a bis-THF motif and the biosynthetic likelihood that **1** would share the common 15*R*-configuration.^[@ref5],[@ref6]^ Our synthetic strategy relied on a late-stage olefination of the C1−C8 aldehyde **2** and a suitable coupling partner derived from the C9−C34 intermediate **3**, as outlined in Scheme [1](#sch1){ref-type="scheme"}. In turn, assembly of the central C15−C28 polyether array found in **3** would arise from the coupling of aldehyde (**4**, C9−C20) and alkyne (**5**, C21−C34), followed by reduction and cyclization to install the C20−C23 THF motif.

![Synthetic Strategy for Chamuvarinin **1**](ol-2010-028699_0005){#sch1}

As outlined in Scheme [2](#sch2){ref-type="scheme"}, the synthesis of the C1−C8 aldehyde **2** started with the alkylation of iodide **6**([@ref7]) with the lithium enolate of lactone **7** to provide **8** in 75% yield.^[@ref8],[@ref9]^ Oxidation to the sulfoxide (mCPBA) and 1,2-syn elimination, followed by cleavage of the C8-benzyl ether with BCl~3~·SMe~2~, provided alcohol **9** (81% over 2 steps).([@ref10]) Finally, Dess−Martin oxidation of **9** provided the C1−C8 aldehyde **2** in excellent yield, as required for the final C8−C9 bond coupling.

![Synthesis of C1−C8 Aldehyde **2**](ol-2010-028699_0006){#sch2}

As shown in Scheme [3](#sch3){ref-type="scheme"}, the synthesis of the C9−C20 subunit **4** began with the Cu(I)-promoted opening of (*S*)-TBS-glycidol ether **10** with allylmagnesium bromide to provide **11** (82%). TBS ether formation (TBSCl, ImH) gave **12** (98%). Ozonolysis and reductive PPh~3~ workup of **12** provided aldehyde **13** which was used directly in the Julia−Kocienski olefination with sulfone **14**([@ref11],[@ref12]) (readily prepared from alcohol **15**([@ref13]) via Mitsunobu with DIAD, PPh~3~, 1H-mercaptophenyltetrazole, and Mo(VI)/H~2~O~2~ oxidation). Treatment of sulfone **14** with NaHMDS in DME at −78 °C, followed by addition of aldehyde **13**, provided olefin **16** in 86% yield from **12** (*E*/*Z* = 97:3). The C16−C19 THF ring was conveniently installed by sequential application of protocols developed by Forsyth and co-workers.^[@ref14],[@ref15]^ Cleavage of the TBS ethers in **16** with TBAF gave diol **17**, which was cleanly converted to epoxide **18** by treatment with NaH and TrisIm (98%).([@ref14]) Subsequent asymmetric dihydroxylation of **18** (AD-mix-β),([@ref16]) followed by base-mediated 5-exo cyclization (K~2~CO~3~, MeOH), provided the 2,5-*anti*-THF diol **19** in 89% yield with \>97:3 dr.([@ref15]) A three-step sequence was then required to complete the C9−C20 aldehyde **4**, involving TBS ether formation (TBSOTf, 2,6-lutidine), selective primary silyl cleavage, and Dess−Martin oxidation (41% over three steps). Using this approach the C9−C20 subunit was completed in ten steps and 21% overall yield from **10**.

![Synthesis of C9−C20 Subunit **4**[](#sch3-fn1)\
PTSH = 1H-mercaptophenyltetrazole; Mo(VI) = (NH~4~)~6~Mo~7~O~24~·4H~2~O.](ol-2010-028699_0007){#sch3}

As outlined in Scheme [4](#sch4){ref-type="scheme"}, the synthesis of the C21−C34 subunit **5** began with the opening of (*S*)-1-epoxyoctane **20**([@ref17]) with homoallylmagnesium bromide([@ref18]) and catalytic CuI to afford **21**. In light of the initial uncertainty around the substitution of the C24−C28 THP ring system in **1**,^1^ we adopted a divergent approach to access both syn-**22** and anti-**23** from **21**. Thus, epoxidation of **21** with mCPBA, followed by addition of catalytic CSA (20 mol %) cleanly promoted the *in situ* 6-exo cyclization to provide readily separable THP alcohols **22** (41%) and **23** (32%). Oxidation of **22** and addition of the lithium anion of trimethylsilylacetylene to the intermediate aldehyde provided **24** with the undesired 23*R* configuration in 88% yield (8:1 dr).([@ref19]) The minor 23*S* diastereomer proved readily separable by column chromatography, and Mitsunobu inversion of the C23-hydroxyl in **24**,([@ref20]) followed by base-mediated methanolysis/desilylation (K~2~CO~3~, MeOH), gave **25** (64%) with the requisite 23*S* configuration. TBS protection (TBSCl/ImH, 91%) then completed the C21−C34 subunit **5** in six steps and 11% overall yield.

![Synthesis of C21−C34 Subunit **5**[](#sch4-fn1)\
Ar = 4-BrC~6~H~4~.](ol-2010-028699_0001){#sch4}

With our key subunits in hand our attention turned to the C20−C21 bond construction and the installation of the central C20−C23 syn-substituted THF motif. In practice, treatment of **5** with *n-*BuLi, followed by addition of the resulting lithium anion to **4**, gave the expected Felkin−Anh adduct **26** in 71% yield with good levels of stereocontrol at C20 (3:1 dr). Diimide reduction of **26** with TsNHNH~2~ and NaOAc in DME at reflux proved the most efficient reduction protocol to afford **27** in 79% yield.([@ref21]) At this point the C20 diastereomers were readily separated by column chromatography.([@ref19]) The stage was now set for the construction of the central C20−C23 THF ring. In the event the C20-hydroxyl in **27** was readily activated as its mesylate (MsCl, Et~3~N), which upon treatment with TBAF promoted silyl ether cleavage and concomitant 5-exo ring closure to provide **3** in excellent yield. At this point, comparison of the ^1^H and ^13^C NMR spectra of the advanced C9−C34 intermediate **3** with the reported data for the C15−C28 region of chamuvarinin showed them to be essentially in complete agreement,^[@ref1],[@ref2]^ providing us with the first clear indication of the correct stereochemical assignment of the relative configuration of the C15−C28 region of chamuvarinin.

With the advanced intermediate **3** in hand, attachment of a suitable C1−C8 subunit at C9 was required to facilitate the completion of chamuvarinin. In considering a suitable C8−C9 coupling reaction, we initially focused on using a C9−C34 aldehyde for olefination with either a C1−C8 Wittig salt or sulfone derived from **9**; however this approach proved unsuccessful. As a result we employed the reversed coupling strategy detailed in Scheme [5](#sch5){ref-type="scheme"}. Thus, the C15-OH in **3** was readily protected as its TBS ether (TBSOTf, 2,6-lutidine, 88%) and subsequent hydrogenolysis of **28** provided alcohol **29** in excellent yield. Treatment of **29** with 1*H*-mercaptophenyltetrazole under Mitsunobu conditions (99%) and subsequent oxidation of the intermediate sulfide (H~2~O~2~, cat Mo(VI), 77%) provided the corresponding sulfone **30**, in readiness for the final C8−C9 Julia−Kocienski olefination.^[@ref11],[@ref12],[@ref22]^ In the event, treatment of sulfone **30** with NaHMDS in THF at −78 °C followed by the addition of aldehyde **2** and warming to −20 °C over 4 h gave the advanced intermediate **31** in 41% yield. Diimide reduction of the C8−C9 alkene (TsNHNH~2~/NaOAc in DME/H~2~O),([@ref21]) followed by deprotection of the C15-TBS ether (3 N HCl, MeOH), provided the 15*R*, 16*R*, 19*R*, 20*R*, 23*S*, 24*S*, 28*S*, 36*S-*diastereomer **32** in excellent yield over two steps. Gratifyingly, the spectroscopic data obtained for **32** (^1^H and ^13^C NMR, IR, and MS) correlated fully with that of natural chamuvarinin.([@ref1]) In the absence of an authentic sample for direct specific rotation and HPLC comparison, the measured specific rotation \[α\]~D~([@ref20]) +9.9 (*c* 0.1, CHCl~3~) \[lit.^1^ +25 (*c* 0.026, CHCl~3~)\] was consistent with that of the natural material. Further convincing evidence for **32** being the correct stereostructure of **1** is provided by the comparable levels of biological activity displayed by the synthetic material. In screening assays against the HeLa cervix cancer cell line and the bloodstream form of the parasite *Trypanasoma brucei*, the synthetic material displayed ED~50~ values of 2.88 ± 0.66 and 1.37 ± 0.08 μM, respectively,([@ref23]) providing unambiguous proof of the relative and absolute configuration of (+)-chamuvarinin (**1**), as that being indicated in structure **32**.

![Completion of Chamuvarinin[](#sch5-fn1)\
PTSH = 1H-mercaptophenyltetrazole; Mo(VI) = (NH~4~)~6~Mo~7~O~24~·4H~2~O.](ol-2010-028699_0002){#sch5}

In conclusion, we have resolved the stereochemical ambiguity surrounding the structure of chamuvarinin by completing the first total synthesis (20 longest linear steps, 1.4% overall yield) and enabling further biological studies. The present work demonstrates the versatility of our modular alkyne coupling/cyclization strategy to construct adjacently linked acetogenin frameworks in an efficient manner to provide synthetic access to these rare bioactive metabolites and for establishing their full stereochemistry.
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